[1] |
Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen[J]. N Engl J Med, 2000, 343(4):230-238. DOI: 10.1056/NEJM200007273430401.
|
[2] |
Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation[J]. N Engl J Med, 2006, 355(13):1318-1330. DOI: 10.1056/NEJMoa061267.
|
[3] |
First WHO global consultation on regulatory requirements for xenotransplantation clinical trials: Changsha, China, 19-21 november 2008. the Changsha Communiqué[J]. Xenotransplantation, 2009, 16(2):61-63. DOI: 10.1111/j.1399-3089.2009.00520.x.
|
[4] |
Hering BJ, Wijkstrom M, Graham ML, et al. Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates[J]. Nat Med, 2006, 12(3):301-303. DOI: 10.1038/nm1369.
|
[5] |
Denner J. Recent progress in xenotransplantation, with emphasis on virological safety[J]. Ann Transplant, 2016, 21:717-727. doi: 10.12659/AOT.900531
|
[6] |
Cardona K, Korbutt GS, Milas Z, et al. Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways[J]. Nat Med, 2006, 12(3):304-306. DOI: 10.1038/nm1375.
|
[7] |
Yi S, Ji M, Wu J, et al. Adoptive transfer with in vitro expanded human regulatory T cells protects against porcine islet xenograft rejection via interleukin-10 in humanized mice[J]. Diabetes, 2012, 61(5):1180-1191. DOI: 10.2337/db11-1306.
|
[8] |
Spizzo T, Denner J, Gazda L, et al. First update of the international xenotransplantation association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--Chapter 2a:source pigs--preventing xenozoonoses[J]. Xenotransplantation, 2016, 23(1):25-31. DOI: 10.1111/xen.12223.
|
[9] |
Paradis K, Langford G, Long Z, et al. Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. the XEN 111 study group[J]. Science, 1999, 285(5431):1236-1241. doi: 10.1126/science.285.5431.1236
|
[10] |
Fishman JA, Scobie L, Takeuchi Y. Xenotransplantation-associated infectious risk: a WHO consultation[J]. Xenotransplantation, 2012, 19(2):72-81. DOI: 10.1111/j.1399-3089.2012.00693.x.
|
[11] |
Onions D, Cooper DK, Alexander TJ, et al. An approach to the control of disease transmission in pig-to-human xenotransplantation[J]. Xenotransplantation, 2000, 7(2):143-155. doi: 10.1034/j.1399-3089.2000.00047.x
|
[12] |
Schuurman HJ. The international xenotransplantation association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--chapter 2: source pigs[J]. Xenotransplantation, 2009, 16(4):215-222. DOI: 10.1111/j.1399-3089.2009.00541.x.
|
[13] |
Niu D, Wei HJ, Lin L, et al. Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9[J]. Science, 2017, 357(6357):1303-1307. DOI: 10.1126/science.aan4187.
|
[14] |
Lau J, Jansson L, Carlsson PO. Islets transplanted intraportally into the liver are stimulated to insulin and glucagon release exclusively through the hepatic artery[J]. Am J Transplant, 2006, (5 Pt 1):967-975. DOI: 10.1111/j.1600-6143.2006.01299.x.
|